German Centre for Cardiovascular Research Cardiomyopathy Register
NCT ID: NCT02187263
Last Updated: 2016-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2300 participants
OBSERVATIONAL
2014-12-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Our objective is to establish an unique national multi-center registry and biobank of well phenotyped patients with non-ischemic cardiomyopathies (CMP) including in depth clinical, molecular and omics-based phenotyping to serve as:
1. central hub for clinical outcome studies.
2. joint resource for diagnostic and therapeutic trials.
3. common biomaterial bank.
4. resource for detailed molecular analyses on patients' biomaterials and patient specific model systems.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sahlgrenska Cardiomyopathy Project
NCT03527342
International Takotsubo Registry (InterTAK Registry)
NCT01947621
The Multicenter Cardiology Monitoring Platform Registry
NCT04976348
The Heart Hive - Cardiomyopathy Study
NCT04612296
The Arrhythmogenic Potential of Midwall Septal Fibrosis in Dilated Cardiomyopathy
NCT05026112
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Well phenotyped patients will be the starting point for comprehensive next-generation genotyping, leading to advanced estimates of genotype-phenotype relationship and its clinical impact.
* Functional analysis of novel genomic loci and their related molecular pathways will be based on our established in-vitro (e.g. iPS cells, yeast two hybrid) and in-vivo (e.g. zebrafish and mice) model systems.
* The integrated analysis of viral load and replication, inflammation, genotype and clinical variables will define risk variables for inflammatory and hereditary CMP.
* By longitudinal follow-up of patients, the role of genetic, epigenetic, metabolic, molecular biomarkers and histopathology for diagnosis and out-come prediction will be defined on a national level.
The registry will also facilitate investigator initiated clinical trials.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
hereditary DCM
No interventions assigned to this group
inflammatory DCM
No interventions assigned to this group
LVNC
No interventions assigned to this group
HCM
No interventions assigned to this group
ARVC
No interventions assigned to this group
acute myocarditis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kerckhoff Klinik
OTHER
University Hospital Goettingen
OTHER
University of Hamburg-Eppendorf
OTHER
University of Kiel
OTHER
University of Luebeck
OTHER
Mainz University
OTHER
University Medical Centre Mannheim
UNKNOWN
Ludwig-Maximilians - University of Munich
OTHER
Medical University of Hannover
OTHER
Department for Community Medicine, University Medicine Greifswald
UNKNOWN
Goethe University
OTHER
Charite University, Berlin, Germany
OTHER
University Hospital Greifswald
OTHER
German Heart Institute
OTHER
ISAR Klinikum Munich
INDUSTRY
Heidelberg University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hugo A Katus, MD
Role: STUDY_CHAIR
Heidelberg University
Wolfgang Hoffmann, MD
Role: STUDY_CHAIR
Department for Community Medicine, University Medicine Greifswald
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Heidelberg
Heidelberg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DZHK TORCH 001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.